Anti-Coagulants - North America

North America

Highlights

The Anti-Coagulants market in North America is anticipated to achieve a revenue of US$17.56bn by 2024.
A steady growth rate of 5.61% is expected between 2024 and 2029, resulting in a market volume of US$23.07bn by 2029.
In the global context, United States will generate the highest revenue, reaching US$16.74bn in 2024.
In North America, the demand for oral anticoagulants is rapidly increasing, driven by the growing aging population and rising prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in North America has been experiencing significant growth in recent years.

Customer preferences: One of the primary drivers of this growth has been the increasing prevalence of cardiovascular diseases in the region. As a result, there has been a rising demand for anti-coagulant drugs that can help prevent blood clots and reduce the risk of heart attacks and strokes. Additionally, there has been a growing trend towards personalized medicine, with patients seeking treatments that are tailored to their specific needs and medical histories. This has led to the development of new, more targeted anti-coagulant therapies that are better able to address individual patient needs.

Trends in the market: In terms of specific trends in the North American anti-coagulants market, there has been a shift towards the use of direct oral anticoagulants (DOACs) over traditional vitamin K antagonists (VKAs). DOACs have several advantages over VKAs, including a lower risk of bleeding and a more predictable dose-response relationship. As a result, they have become increasingly popular among both physicians and patients. Another trend in the market has been the growing use of combination therapies, which involve the use of multiple anti-coagulant drugs in order to achieve better outcomes.

Local special circumstances: There are also several local factors that have contributed to the growth of the anti-coagulants market in North America. For example, the region has a large and aging population, which has led to an increase in the number of patients with cardiovascular diseases. Additionally, the high cost of healthcare in the region has made it more difficult for patients to access certain treatments, leading to a greater emphasis on preventative care and the use of anti-coagulants to reduce the risk of more serious health problems.

Underlying macroeconomic factors: Finally, there are several underlying macroeconomic factors that have contributed to the growth of the anti-coagulants market in North America. These include the overall growth of the healthcare industry in the region, as well as the increasing focus on innovation and the development of new therapies. Additionally, the region's strong intellectual property laws and regulatory environment have made it an attractive market for pharmaceutical companies looking to invest in research and development. Overall, these factors have helped to create a favorable environment for the growth of the anti-coagulants market in North America.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.